Health Canada
www.hc-sc.gc.ca
Common menu bar links
Important Information - TOPAMAX (topiramate) - Janssen Othro Inc.
Date: 2003-07-17
Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.
(PDF Version - 22 K)Contact
BCANS Enquiries
This is duplicated text of a letter from Janssen-Ortho Inc. Contact the company for a copy of any references, attachments or enclosures.
IMPORTANT DRUG SAFETY INFORMATION
July 11, 2003
SUBJECT: Reports of Oligohidrosis (decreased sweating) and Hyperthermia in patients treated with TOPAMAX* (topiramate)
Dear Healthcare Professional:
Janssen-Ortho Inc., following discussions with Health Canada, would like to inform you of important safety information pertaining to rare reports, primarily in children, of oligohidrosis (decreased sweating) and hyperthermia in patients treated with TOPAMAX (topiramate).
The Prescribing Information for TOPAMAX was revised in February 2003. Additional changes, including relocation of information on oligohidrosis and hyperthermia to the Warnings and Precautions section, are being introduced at this time. Please carefully review the information noted below:
These reports have primarily involved children. Patients treated with TOPAMAX, especially pediatric patients, should be monitored closely for evidence of decreased sweating and increased body temperature, particularly in hot weather. Proper hydration before and during activities such as exercise or exposure to warm temperatures is recommended.
Caution should be used when TOPAMAX is prescribed with other drugs that predispose patients to heat-related disorders; these drugs include, but are not limited to, other carbonic anhydrase inhibitors and drugs with anticholinergic activity.
BACKGROUND INFORMATION
Clinical Trial Data:
As of February 2002, the reporting rate of all potential cases of oligohidrosis was 0.25%.
Spontaneous Post-marketing Reports:
As of February 2002, review of spontaneous post-marketing reports suggests that the rate
of adverse events that potentially involve oligohidrosis is approximately 35 per 1,000,000
patients treated (including 1 reported case in Canada). Serious or clinically significant
oligohidrosis or its sequelae were reported at a rate of 1.6 per 1,000,000 patients treated.
As only a small proportion of suspected adverse events are usually reported, caution should
be exercised in estimating the incidence of these adverse events.
Janssen-Ortho Inc. continues to work closely with Health Canada to monitor ongoing clinical trials, and worldwide pharmacovigilance reports. Janssen-Ortho Inc. will continue to provide you with the most current and complete product information available for the management of patients receiving TOPAMAX.
The current Prescribing Information is available on the Janssen-Ortho Inc. website at 
http://www.janssen-ortho.com Updates to the Prescribing Information will be posted on this website
and will be provided for the next edition of the Compendium of Pharmaceuticals and Specialties.
The identification, characterization and management of drug-related adverse events are dependent on the active participation of Healthcare Professionals in adverse event reporting programs. Healthcare Professionals are asked to report any suspected adverse events in patients receiving TOPAMAX (topiramate) to Janssen-Ortho Inc. at the following address:
Janssen-Ortho Inc.
Drug Safety and Surveillance
19 Green Belt Drive
Toronto, ON M3C 1L9 or
call toll free at 1-800-567-3331 or
email to dsscan@joica.jnj.com
Your professional commitment in this matter has an important role in protecting the well-being of your patients by contributing to early signal detection and informed use of drugs.
Should you have any questions or require additional information regarding the use of TOPAMAX (topiramate), please contact Janssen-Ortho Inc. Medical Information Department at 1-800-567-3331 from 9:00 a.m. to 5:00 p.m., Monday through Friday, EST.
Sincerely,
original signed by
Wendy Arnott, Pharm.D.
Vice-President
Brand Integrity and Approvals
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 0201C2
OTTAWA, Ontario, K1A 1B9
Tel: (613) 957-0337 or Fax: (613) 957-0335
Toll free for consumers and health professionals:
Tel: 866 234-2345, Fax: 866 678-6789
cadrmp@hc-sc.gc.ca
The AR Reporting Form and the AR Guidelines can be found on the TPD web site or in The Canadian Compendium of Pharmaceuticals and Specialties.
